Loading...
XNASSYRS
Market cap5mUSD
Dec 26, Last price  
0.22USD
1D
6.41%
1Q
-89.21%
Jan 2017
-99.82%
IPO
-99.89%
Name

Syros Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:SYRS chart
P/E
—
P/S
0.58
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
54.04%
Rev. gr., 5y
37.12%
Revenues
10m
-33.23%
00317,000317,0001,101,0002,050,0001,982,00015,093,00023,488,00014,880,0009,936,000
Net income
-165m
L+233.81%
-9,259,000-13,431,000-29,818,000-47,743,000-54,010,000-62,279,000-75,438,000-85,830,000-90,465,000-49,301,000-164,574,000
CFO
-110m
L-10.85%
-7,194,000-11,969,000-23,030,000-40,536,000-44,729,000-40,315,000-60,253,000-57,364,000-99,540,000-123,065,000-109,707,000
Earnings
Mar 25, 2025

Profile

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
URL
https://syros.com/
IPO date
Jun 30, 2016
Employees
117
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
9,936
-33.23%
14,880
-36.65%
23,488
55.62%
Cost of revenue
138,687
144,210
122,908
Unusual Expense (Income)
NOPBT
(128,751)
(129,330)
(99,420)
NOPBT Margin
Operating Taxes
(45,353)
3,907
Tax Rate
NOPAT
(128,751)
(83,977)
(103,327)
Net income
(164,574)
233.81%
(49,301)
-45.50%
(90,465)
5.40%
Dividends
Dividend yield
Proceeds from repurchase of equity
43,270
119,978
70,776
BB yield
-19.61%
-264.57%
-34.72%
Debt
Debt current
11,315
2,071
2,011
Long-term debt
73,936
84,422
88,114
Deferred revenue
Other long-term liabilities
61,747
24,472
3,029
Net debt
(54,275)
(118,897)
(53,282)
Cash flow
Cash from operating activities
(109,707)
(123,065)
(99,540)
CAPEX
(272)
(1,241)
(1,245)
Cash from investing activities
37,337
67,185
(52,653)
Cash from financing activities
43,462
131,045
70,511
FCF
(123,574)
(81,352)
(100,971)
Balance
Cash
139,526
202,304
130,369
Long term investments
3,086
13,038
Excess cash
139,029
204,646
142,233
Stockholders' equity
(722,781)
(558,111)
(463,597)
Invested Capital
865,589
773,890
617,035
ROIC
ROCE
EV
Common stock shares outstanding
28,326
12,632
6,253
Price
7.79
116.99%
3.59
-88.99%
32.60
-69.95%
Market cap
220,658
386.58%
45,349
-77.76%
203,864
-59.20%
EV
166,383
(73,548)
150,582
EBITDA
(126,499)
(126,363)
(96,402)
EV/EBITDA
0.58
Interest
5,127
4,134
3,907
Interest/NOPBT